



## MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

**Lyon, France, July 13, 2023 – 6:00 pm CET – [MaaT Pharma \(EURONEXT: MAAT – the “Company”\)](#), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to improving survival outcomes for patients with cancer, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.**

Under the liquidity contract entered on June 30<sup>th</sup>, 2023, between Maat Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account:

- 15,484 shares
- € 41,285.13
  
- Number of executions on buy side on semester: 552
- Number of executions on sell side on semester: 431
- Traded volume on buy side on semester: 15,974 shares for € 144,745.75
- Traded volume on sell side on semester: 12,997 shares for € 122,384.16

As a reminder:

- the following resources appeared on the last half year statement on December 31<sup>st</sup>, 2022, on the liquidity account:
  - 12,507 shares
  - € 63,045.61
  
  - Number of executions on buy side on semester: 390
  - Number of executions on sell side on semester: 330
  - Traded volume on buy side on semester: 14,188 shares for € 131,237.39
  - Traded volume on sell side on semester: 9,342 shares for € 86,141.8
  
- the following resources appeared on the liquidity account when the activity started:
  - 0 shares
  - € 200,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22<sup>nd</sup>, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>552</b>	<b>15,974</b>	<b>144,745.75</b>	<b>431</b>	<b>12,997</b>	<b>122,384.16</b>
				4	67	539.35
02/01/2023	1	1	8.02	2	20	161.60
03/01/2023	1	5	40.00	14	460	3,910.00
04/01/2023	-	-	-	14	493	4,757.45
05/01/2023	9	281	2,554.29	-	-	-
06/01/2023	4	88	796.40	-	-	-
09/01/2023	5	261	2,268.09	1	1	8.62
10/01/2023	2	41	348.50	2	49	416.50
11/01/2023	6	139	1,167.60	-	-	-
12/01/2023	8	222	1,847.04	8	220	1,867.80
13/01/2023	-	-	-	5	150	1,326.00
16/01/2023	8	200	1,726.00	2	41	360.80
17/01/2023	2	60	519.00	1	40	348.00
18/01/2023	2	70	602.00	4	59	522.15
19/01/2023	-	-	-	4	250	2,250.00
20/01/2023	4	130	1,140.10	1	30	258.00
23/01/2023	2	50	424.00	4	62	543.74
24/01/2023	1	1	8.62	15	499	4,525.93
25/01/2023	5	185	1,650.20	6	201	1,839.15
26/01/2023	4	71	641.13	2	63	580.86
27/01/2023	3	60	546.00	5	67	623.10
30/01/2023	1	50	460.00	2	51	469.20
31/01/2023	2	51	464.10	4	51	472.26
01/02/2023	3	101	924.15	7	300	2,703.00
02/02/2023	4	185	1,652.05	21	596	5,673.92
03/02/2023	-	-	-	4	150	1,440.00
06/02/2023	13	502	4,663.58	1	50	467.00
07/02/2023	4	174	1,599.06	7	300	2,814.00
08/02/2023	20	654	5,886.00	6	152	1,377.12
09/02/2023	8	330	2,880.90	4	140	1,261.40
10/02/2023	5	202	1,801.84	5	180	1,562.40
13/02/2023	7	353	3,014.62	5	131	1,151.49
14/02/2023	3	110	957.00	3	80	707.20
15/02/2023	4	112	976.64	9	311	2,839.43
16/02/2023	3	90	812.70	1	50	460.00
17/02/2023	5	61	559.98	6	199	1,864.63
20/02/2023	3	98	909.44	3	51	474.30
21/02/2023	3	73	675.98	16	689	6,724.64
22/02/2023	4	63	598.50	5	155	1,488.00
23/02/2023	7	144	1,368.00	13	510	5,120.40
24/02/2023	7	215	2,126.35	-	-	-
27/02/2023	4	100	1,005.00	2	106	1,061.06
28/02/2023	3	105	1,033.20	16	1,071	11,288.34
01/03/2023	4	120	1,207.20	-	-	-
02/03/2023	6	105	1,121.40	8	350	3,853.50
03/03/2023	16	450	4,846.50	4	148	1,567.32
06/03/2023	5	184	1,928.32	4	121	1,291.07
07/03/2023	5	76	801.04	3	41	442.80
08/03/2023	4	94	1,000.16	3	30	303.00
09/03/2023	17	583	5,853.32	-	-	-
10/03/2023	3	60	595.80	1	60	576.00
13/03/2023	20	730	6,942.30			

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>552</b>	<b>15,974</b>	<b>144,745.75</b>	<b>431</b>	<b>12,997</b>	<b>122,384.16</b>
14/03/2023	6	80	765.60	5	160	1,556.80
15/03/2023	6	151	1,449.60	1	1	9.72
16/03/2023	3	51	484.50	3	41	393.60
17/03/2023	5	150	1,438.50	3	64	627.20
20/03/2023	1	40	376.00	1	40	380.00
21/03/2023	4	41	389.50	1	1	9.58
22/03/2023	1	26	247.00	4	146	1,416.20
23/03/2023	2	50	489.00	2	39	384.93
24/03/2023	20	495	4,653.00	4	77	730.73
27/03/2023	14	306	2,836.62	12	369	3,516.57
28/03/2023	3	95	949.05	13	365	3,719.35
29/03/2023	12	330	3,313.20	3	60	621.00
30/03/2023	3	36	355.32	3	70	697.20
31/03/2023	2	51	510.00	6	200	2,054.00
03/04/2023	1	18	180.00	-	-	-
04/04/2023	5	83	830.00	2	6	60.54
05/04/2023	2	70	700.00	1	12	121.20
06/04/2023	2	51	510.00	3	11	111.10
11/04/2023	5	50	500.00	-	-	-
12/04/2023	9	158	1,537.34	3	90	887.40
13/04/2023	7	90	894.60	-	-	-
14/04/2023	7	210	2,037.00	2	50	490.00
17/04/2023	13	375	3,562.50	2	65	624.00
18/04/2023	3	120	1,138.80	3	32	304.32
19/04/2023	2	80	752.00	3	49	465.50
21/04/2023	2	20	190.00	-	-	-
24/04/2023	6	243	2,340.09	10	339	3,328.98
25/04/2023	3	100	977.00	4	160	1,580.80
26/04/2023	1	1	9.72	1	1	9.72
27/04/2023	4	110	1,052.70	-	-	-
28/04/2023	16	528	4,778.40	4	170	1,558.90
02/05/2023	3	50	454.00	-	-	-
03/05/2023	1	1	9.08	1	1	9.08
04/05/2023	9	230	2,017.10	4	19	167.39
05/05/2023	-	-	-	7	92	821.56
08/05/2023	7	146	1,278.96	1	1	8.92
09/05/2023	3	60	522.00	3	50	440.00
10/05/2023	6	214	1,821.14	2	50	440.00
11/05/2023	8	156	1,285.44	3	87	727.32
12/05/2023	1	1	8.28	4	84	709.80
15/05/2023	4	131	1,074.20	4	170	1,434.80
16/05/2023	3	110	936.10	4	100	865.00
17/05/2023	1	40	332.00	-	-	-
19/05/2023	6	354	2,842.62	-	-	-
22/05/2023	1	50	400.00	-	-	-
23/05/2023	5	40	320.00	-	-	-
24/05/2023	1	1	7.98	3	41	328.00
25/05/2023	3	50	400.00	-	-	-
29/05/2023	-	-	-	5	101	828.20
30/05/2023	2	31	251.10	1	1	8.20
31/05/2023	1	50	400.00	-	-	-

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>552</b>	<b>15,974</b>	<b>144,745.75</b>	<b>431</b>	<b>12,997</b>	<b>122,384.16</b>
01/06/2023	1	1	7.98	1	1	7.98
05/06/2023	2	30	240.00	1	30	243.00
06/06/2023	3	170	1,353.20	1	1	8.20
07/06/2023	3	151	1,182.33	1	1	7.90
08/06/2023	3	91	715.26	1	1	7.90
09/06/2023	4	91	707.07	2	51	402.90
12/06/2023	6	256	1,966.08	3	64	493.44
13/06/2023	2	80	616.00	4	112	873.60
14/06/2023	4	116	886.24	4	67	513.22
15/06/2023	3	140	1,045.80	1	27	202.50
16/06/2023	1	3	22.50	4	80	608.00
19/06/2023	8	282	2,092.44	3	160	1,214.40
21/06/2023	-	-	-	2	60	448.20
22/06/2023	2	70	520.80	-	-	-
23/06/2023	4	101	737.30	3	61	457.50
26/06/2023	1	1	7.28	1	1	7.28
27/06/2023	-	-	-	1	20	148.00
28/06/2023	5	194	1,402.62	-	-	-
29/06/2023	4	203	1,467.69	-	-	-
30/06/2023	1	30	216.00	-	-	-

## About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).



## Contacts

### MaaT Pharma – Investor Relations

Guillaume Debroas, Ph.D.  
Head of Investor Relations  
+33 6 16 48 92 50  
[invest@maat-pharma.com](mailto:invest@maat-pharma.com)

### MaaT Pharma – Media Relations

Pauline RICHAUD  
Senior PR & Corporate Communications  
Manager  
+33 6 14 06 45 92  
[media@maat-pharma.com](mailto:media@maat-pharma.com)

### Trophic Communications – Corporate Communications

Charlotte SPITZ or  
Stephanie MAY  
+49 171 351 2733  
[maat@trophic.eu](mailto:maat@trophic.eu)